MedTrace Logo

Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health

NCT07087431 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2026-03-23

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.

Conditions

Interventions

BEHAVIORAL

Immediate disclosure of CAD PRS results

Participants receive their CAD PRS results as soon as they are available after genotyping.

BEHAVIORAL

Deferred Disclosure of CAD PRS results

Participants receive their CAD PRS results after completion of the 12 month follow up period.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2026-10-15
Completion
2027-08-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07087431 on ClinicalTrials.gov